pharma collaborations

View All

pharma happenings for BMS Sanofi GW Pharmaceuticals Kiadis
Bristol Myers’ psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm’s Xpovio; Kiadis USD 358M Buyout

Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's Otezla Bristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial in patients with moderate to severe plaque psoriasis. Deucravaci...

Find More

Pharma news for Bayer, Novartis, Forma, AskBio
Bayer eyes AskBio’s Gene Therapies; Novartis’ Iptacopan; Forma’s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic

Bayer Set to Fork Over USD 4 Billion for AskBio’s Gene Therapies Germany-based Bayer is set to acquire North Carolina-based Asklepios BioPharmaceutical (AskBio) with motives to get its hands on its gene therapies.  Bayer will pay USD 2 billion in upfront payment in exchange for AskBio's AAV-based gene th...

Find More

Pharma happenings and latest COVID-19 News
AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership

AstraZeneca demonstrates positive early results from its trial evaluating COVID-19 vaccine-AZD1222 In a frenzied race to find a global cure for COVID-19, several pharma players are testing waters and presenting results from clinical studies evaluating their potential candidates. Not long after, Moderna, a U...

Find More

Latest Pharma Happenings
Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies

Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19.   Regeneron is running two trials simultaneously, one for prevention and other for treatment, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Phase III trial is studyi...

Find More

Delveinsight
Business Cocktail

Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be used to promote nonopioid pain drug candidate CNTX-4975 into a phase 3 trial with patients suffering from knee osteoarth...

Find More